This "Graft Versus Host Disease (GvHD)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease (GvHD), historical and forecasted epidemiology as well as the Graft Versus Host Disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.The 7Mm Market of Graft Versus Host Disease (GvHD) was USD 353.5 Million in 2016, and is Expected to Increase at a CAGR from 2016-2027
The Graft Versus Host Disease (GvHD) market report provides current treatment practices, emerging drugs, Graft Versus Host Disease (GvHD) market share of the individual therapies, current and forecasted Graft Versus Host Disease (GvHD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Graft Versus Host Disease (GvHD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Graft Versus Host Disease (GvHD) Disease Understanding and Treatment Algorithm
The Graft Versus Host Disease (GvHD) market report gives a thorough understanding of the Graft Versus Host Disease (GvHD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Graft Versus Host Disease (GvHD).
Treatment
It covers the details of conventional and current medical therapies available in the Graft Versus Host Disease (GvHD) market for the treatment of the condition. It also provides Graft Versus Host Disease (GvHD) treatment algorithms and guidelines in the United States, Europe, and Japan.
Graft Versus Host Disease (GvHD) Epidemiology
The Graft Versus Host Disease (GvHD) epidemiology division provide insights about historical and current Graft Versus Host Disease (GvHD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Graft Versus Host Disease (GvHD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Graft Versus Host Disease (GvHD) Epidemiology
The epidemiology segment also provides the Graft Versus Host Disease (GvHD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Graft Versus Host Disease (GvHD) Drug Chapters
Drug chapter segment of the Graft Versus Host Disease (GvHD) report encloses the detailed analysis of Graft Versus Host Disease (GvHD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Graft Versus Host Disease (GvHD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Graft Versus Host Disease (GvHD) treatment.
Graft Versus Host Disease (GvHD) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Graft Versus Host Disease (GvHD) treatment.
Graft Versus Host Disease (GvHD) Market Outlook
The Graft Versus Host Disease (GvHD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Graft Versus Host Disease (GvHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Graft Versus Host Disease (GvHD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Graft Versus Host Disease (GvHD) market in 7MM is expected to change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Graft Versus Host Disease (GvHD) market in 7MM.
The United States Market Outlook
This section provides the total Graft Versus Host Disease (GvHD) market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Graft Versus Host Disease (GvHD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Graft Versus Host Disease (GvHD) market size and market size by therapies in Japan is also mentioned.
Graft Versus Host Disease (GvHD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Graft Versus Host Disease (GvHD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Graft Versus Host Disease (GvHD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Graft Versus Host Disease (GvHD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Graft Versus Host Disease (GvHD) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Graft Versus Host Disease (GvHD) emerging therapies.
Reimbursement Scenario in Graft Versus Host Disease (GvHD)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL-Views
To keep up with current market trends, we take KOLs and SME's opinion working in Graft Versus Host Disease (GvHD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Graft Versus Host Disease (GvHD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitive and Market Intelligence analysis of the Graft Versus Host Disease (GvHD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Graft Versus Host Disease (GvHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Graft Versus Host Disease (GvHD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Graft Versus Host Disease (GvHD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Graft Versus Host Disease (GvHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Graft Versus Host Disease (GvHD) market
Report Highlights
- In the coming years, Graft Versus Host Disease (GvHD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Graft Versus Host Disease (GvHD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Graft Versus Host Disease (GvHD). Launch of emerging therapies will significantly impact the Graft Versus Host Disease (GvHD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Graft Versus Host Disease (GvHD)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Graft Versus Host Disease (GvHD) Report Insights
- Patient Population
- Therapeutic Approaches
- Graft Versus Host Disease (GvHD) Pipeline Analysis
- Graft Versus Host Disease (GvHD) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Graft Versus Host Disease (GvHD) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Graft Versus Host Disease (GvHD) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Graft Versus Host Disease (GvHD) Report Assessment
Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions Answered
Market Insights:
- What was the Graft Versus Host Disease (GvHD) market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Graft Versus Host Disease (GvHD) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Graft Versus Host Disease (GvHD) market size during the forecast period (2019-2032)?
- At what CAGR, the Graft Versus Host Disease (GvHD) market is expected to grow in 7MM during the forecast period (2019-2032)?
- What would be the Graft Versus Host Disease (GvHD) market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Graft Versus Host Disease (GvHD) market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Graft Versus Host Disease (GvHD)?
- What is the historical Graft Versus Host Disease (GvHD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Graft Versus Host Disease (GvHD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Graft Versus Host Disease (GvHD)?
- Out of all 7MM countries, which country would have the highest prevalent population of Graft Versus Host Disease (GvHD) during the forecast period (2019-2032)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Graft Versus Host Disease (GvHD) treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Graft Versus Host Disease (GvHD) in the USA, Europe, and Japan?
- What are the Graft Versus Host Disease (GvHD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Graft Versus Host Disease (GvHD)?
- How many therapies are developed by each company for Graft Versus Host Disease (GvHD) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Graft Versus Host Disease (GvHD) treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Graft Versus Host Disease (GvHD) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Graft Versus Host Disease (GvHD) and their status?
- What are the key designations that have been granted for the emerging therapies for Graft Versus Host Disease (GvHD)?
- What are the global historical and forecasted market of Graft Versus Host Disease (GvHD)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Graft Versus Host Disease (GvHD) market
- To understand the future market competition in the Graft Versus Host Disease (GvHD) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Graft Versus Host Disease (GvHD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Graft Versus Host Disease (GvHD) market
- To understand the future market competition in the Graft Versus Host Disease (GvHD) market
Table of Contents
Executive Summary
Graft versus Host Disease (GvHD) - Disease Understanding and Treatment Algorithm
The Graft versus Host Disease (GvHD) market report gives the thorough understanding of the Graft versus Host Disease (GvHD) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Graft versus Host Disease (GvHD) in the US, Europe, and Japan.
Graft versus Host Disease (GvHD) Epidemiology
The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]. The epidemiology section of report further includes diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs). It also includes diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs.
The diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) in 7 major markets was 53,601 (which includes 21,408 Incident cases of first allogeneic HSCT) in 2016 and, is expected to increase during the study period i.e., 2016-2027. Among 7MM United States account for highest diagnosed incident cases of aGvHD and cGvHD in diagnosed incident cases of First Allogeneic HSCTs followed by Germany.
Graft versus Host Disease (GvHD) Drug Chapters
This segment of the Graft versus Host Disease (GvHD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Presently, the GvHD market comprises of majorly off-label drugs. Off-label drugs used in treatment and prevention of GvHD includes Corticosteroids (methylprednisolone and prednisolone), Calcineurin inhibitors (Cyclosporine), IL2Ra (CD25) inhibitors (Simulect), TNFa inhibitors (Remicade and Enbrel), Co-stimulatory blockers (Orencia and Nulojix), mTOR inhibitors (Rapamune and Certican), SOT therapies (CellCept/Myfortic and Prograf), Anti-neoplastic therapies (Velcade, Gleevec, Methotrexate, Nipent and Cyclophosphamide) and other biologics (Lemtrada and Rituxan/MabThera).
Currently there are three approved therapies for GvHD including Imbruvica (in US for cGvHD), Remestemcel-L (in Japan for aGvHD) and Grafalon (in Germany for prophylaxis of GvHD). Detailed chapters for all of these drugs, along with the promising upcoming therapies have been covered in the report.
Graft versus Host Disease (GvHD) Market Outlook
The Graft versus Host Disease (GvHD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
GvHD market size is segmented into Prophylaxis and Therapeutics. Therapeutics section is further subcategorized into aGvHD and cGvHD. The 7MM market of Graft versus Host Disease (GvHD) was USD 353.5 million in 2016, and is expected to increase at a CAGR from 2016-2027.
Graft versus Host Disease (GvHD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Graft versus Host Disease (GvHD) includes the drug-uptake for individual therapies, which is further segmented which is further segmented in prophylaxis and therapeutics.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AltruBio
- Amgen
- AstraZeneca
- Biogen
- Bristol-Myers Squibb
- CSL Behring
- CTI BioPharma
- ElsaLys Biotech (Mediolanum Farmaceutici Spa)
- Equillium/Biocon
- GlaxoSmithKline
- Incyte Corporation
- Jazz Pharmaceuticals
- Kadmon Corporation
- MaaT Pharma
- Medac
- Millennium Pharmaceuticals/Takeda Oncology
- Novartis
- OncoImmune/Merck (MSD)
- Pfizer
- Regimmune Corporation
- Roche-Genentech
- Syndax Pharmaceutical
- Synthetic Biologics
- Takeda
- Xenikos
